Welche Hunde bekommen DCM am häufigsten?

Dobermann Pinscher (bis 58 % Prävalenz), Irischer Wolfshund, Boxer (Sonderform ARVC), Neufundländer, Deutsche Dogge und Deerhound. Beim Dobermann gibt es eine erbliche Form mit okkultem Verlauf — jährliches Screening (Holter-EKG + Echo) ab 3–4 Jahren ist Standard.

Wie wird DCM beim Hund behandelt?

Pimobendan (verbessert Herzkontraktion), ACE-Hemmer (Nachlastsenkung), Diuretika (bei Stauung). Beginn je nach Stadium: im okkulten Stadium B2 verbessert frühzeitiger Pimobendan-Start die Prognose nachweislich (PROTECT-Studie).

Wie lange lebt ein Hund mit DCM?

Stark rassen- und stadienabhängig. Dobermänner haben kürzeste Überlebensdauer (median 6–9 Monate nach Symptombeginn). Bei anderen Rassen und frühzeitigem Therapiebeginn: 1–3 Jahre möglich. Mit optimierter Medikation lange gute Lebensqualität erreichbar.

Health & Diseases

Dilated cardiomyopathy in dogs: diagnosis and treatment

Dilated cardiomyopathy (DCM) is a disease of the heart muscle in which the left (and later both) ventricles enlarge and the pumping function deteriorates. The heart pumps too little blood into the body, leading to heart failure with congestion in the lungs or abdomen.

Auf einen Blick

Dilated cardiomyopathy (DCM) is a disease of the heart muscle in which the left (and later both) ventricles enlarge and the pumping function deteriorates. The heart pumps too little blood into the body, leading to heart failure with congestion in the lungs or abdomen.
Risiko-Hinweis: low-medium: Consider context and individual differences
Wissenschaftliche Einordnung: Wess et al. (2010, Journal of Veterinary Internal Medicine, PubMed 20412393) investigated DCM prevalence in Dobermans over 4 years: 58% of all Dobermans examined developed DCM — a shockingly high rate. The disease was often occult (without clinical symptoms) for months to years before the onset of heart failure or sudden cardiac death. Holter monitoring (24-h ECG) and echocardiography are therefore recommended annually for Dobermans from 3–4 years of age.Tidholm and Jonsson (1997, Journal of the American Animal Hospital Association, PubMed 9141478) retrospectively analyzed 189 dogs with DCM: Median survival time after diagnosis was 6.5 months — with significant variability depending on breed and disease stage. Dobermans had the shortest survival time. Cardiac glycosides, diuretics, and ACE inhibitors measurably improved survival time and quality of life.Martin et al. (2010, Journal of Small Animal Practice, PubMed 20840134) evaluated owner assessment of survival time and quality of life in heart disease: Most owners rated the quality of life of their cardiac dogs as good to very good, as long as symptoms were medically controlled. Owner information about the course of the disease and medication significantly improved compliance and satisfaction.

Dilated cardiomyopathy in dogs: diagnosis and treatment

What is dilated cardiomyopathy in dogs?

Dilated cardiomyopathy (DCM) is a disease of the heart muscle in which the left (and later both) ventricles enlarge and pumping function declines. The heart pumps too little blood into the body — heart failure develops, with congestion in the lungs or abdominal cavity.

DCM is the most common heart disease in large and giant breeds: Doberman Pinschers, Irish Wolfhounds, Boxers, Newfoundlands, Deerhounds, and Great Danes are particularly affected. An inherited form has been identified in Dobermans; in Boxers, a specific form occurs (ARVC, arrhythmogenic right ventricular cardiomyopathy).

Background + scientific classification

Wess et al. (2010, Journal of Veterinary Internal Medicine, PubMed 20412393) investigated DCM prevalence in Dobermans over 4 years: 58% of all Dobermans examined developed DCM — an alarmingly high rate. The disease often progressed occultly (without clinical symptoms) for months to years before the onset of heart failure or sudden cardiac death. Holter monitoring (24-hour ECG) and echocardiography are therefore recommended annually for Dobermans from 3–4 years of age.

Tidholm and Jonsson (1997, Journal of the American Animal Hospital Association, PubMed 9141478) retrospectively analyzed 189 dogs with DCM: median survival time after diagnosis was 6.5 months — with considerable variability depending on breed and disease stage. Dobermans had the shortest survival time. Cardiac glycosides, diuretics, and ACE inhibitors measurably improved survival time and quality of life.

Martin et al. (2010, Journal of Small Animal Practice, PubMed 20840134) evaluated dog owner assessments of survival time and quality of life in heart disease: most dog owners rated the quality of life of their dogs with cardiac disease as good to very good, as long as symptoms were controlled with medication. Dog owner information about disease progression and medication significantly improved compliance and satisfaction.

Vitomalia Position

DCM is a serious disease with a genetic component that should be screened for early in at-risk breeds. Sudden cardiac death caused by malignant arrhythmias is a real risk — and in some cases can be prevented through early detection via Holter ECG and echocardiography. Anyone who has a young Doberman and does not arrange annual cardiac screening is acting negligently toward the animal.

When does dilated cardiomyopathy in dogs become relevant?

In cases of exercise intolerance, coughing, or rapid fatigue in large breeds
In cases of syncope (fainting episodes) — a sign of malignant cardiac arrhythmias
For Dobermans: annual screening from 3–4 years of age (Holter + echocardiography) is recommended
In ascites (abdominal fluid accumulation): assess right-sided heart failure as a cause
In discussions of diet-related DCM: taurine and carnitine deficiency (grain-free diets)

Practical application

DCM stages and treatment (simplified according to ACVIM):

Stage	Finding	Treatment
A	At-risk breed, no findings	Annual screening
B1	Echocardiographic finding, no symptoms, no remodeling	Screening, discuss pimobendan if appropriate
B2	Echocardiographic finding with left ventricular remodeling	Pimobendan, ACE inhibitors
C	Clinical heart failure	Pimobendan + diuretics + ACE inhibitors
D	Refractory heart failure	Intensified therapy, palliative care

Key medication principles: - Pimobendan: improves contractility and prolongs survival - Furosemide: diuretic for congestion (pulmonary edema, ascites) - ACE inhibitors: afterload reduction, slowing of remodeling

Common mistakes & myths

“My dog is coughing; it’s bronchitis.” Coughing in large breeds can indicate heart failure with pulmonary edema. Any persistent cough in a Doberman, Boxer, or Irish Wolfhound requires a cardiac workup.
“Heart problems are recognized in time.” DCM in Dobermans remains occult for months — without ECG and echocardiography, early detection is not possible. Clinical signs often appear only at an advanced stage.
“Grain-free food causes DCM.” The FDA investigation in 2018–2019 into grain-free diets and DCM showed an association, not causal proof. Taurine supplementation in affected dogs led to recovery in some cases. There is currently no clear evidence of a general causal link — but caution is advisable with one-sided exotic-protein diets.

Scientific status 2026

Genetic tests for DCM-associated mutations in Dobermans (PDK4 gene, among others) are available. According to the PROTECT study, pimobendan in the occult stage (before symptoms) significantly extends the time to heart failure. Research on taurine in connection with grain-free diets is ongoing; clear proof of causality is still lacking.

Frequently asked questions

Which dogs get DCM most often?

Doberman Pinscher (up to 58% prevalence), Irish Wolfhound, Boxer (special form ARVC), Newfoundland, Great Dane and Deerhound. In Dobermans, there is an inherited form with an occult course — annual screening from 3–4 years of age is standard.

How is DCM treated in dogs?

Medication-based: pimobendan (to improve heart contraction), ACE inhibitors (to reduce afterload), diuretics (to treat congestion). Treatment starts depending on the stage. In the occult stage B2, starting pimobendan early has been shown to improve the prognosis.

How long does a dog with DCM live?

Strongly dependent on breed and disease stage. Dobermans have the shortest survival time (median 6–9 months after symptom onset). In other breeds and with early treatment: 1–3 years may be possible. Quality of life can remain good for a long time with optimized medication.

Related terms

Sources & further reading

Wess, G., Schulze, A., Butz, V., Simak, J., Killich, M., Keller, L. J. M., Maeurer, J., & Hartmann, K. (2010). Prevalence of dilated cardiomyopathy in Doberman Pinschers in various age groups. Journal of Veterinary Internal Medicine, 24(3), 533–538. https://pubmed.ncbi.nlm.nih.gov/20412393/
Tidholm, A., & Jonsson, L. (1997). A retrospective study of canine dilated cardiomyopathy (189 cases). Journal of the American Animal Hospital Association, 33(6), 544–550. https://pubmed.ncbi.nlm.nih.gov/9141478/
Martin, M. W. S., Stafford Johnson, M. J., & Strehlau, G. (2010). Canine dilated cardiomyopathy: a retrospective study of signalment, presentation and cardiac status in dogs attending a veterinary referral centre. Journal of Small Animal Practice, 51(10), 507–514. https://pubmed.ncbi.nlm.nih.gov/20840134/

Wissenschaftliche Einordnung

Wess et al. (2010, Journal of Veterinary Internal Medicine, PubMed 20412393) investigated DCM prevalence in Dobermans over 4 years: 58% of all Dobermans examined developed DCM — a shockingly high rate. The disease was often occult (without clinical symptoms) for months to years before the onset of heart failure or sudden cardiac death. Holter monitoring (24-h ECG) and echocardiography are therefore recommended annually for Dobermans from 3–4 years of age.

Tidholm and Jonsson (1997, Journal of the American Animal Hospital Association, PubMed 9141478) retrospectively analyzed 189 dogs with DCM: Median survival time after diagnosis was 6.5 months — with significant variability depending on breed and disease stage. Dobermans had the shortest survival time. Cardiac glycosides, diuretics, and ACE inhibitors measurably improved survival time and quality of life.

Martin et al. (2010, Journal of Small Animal Practice, PubMed 20840134) evaluated owner assessment of survival time and quality of life in heart disease: Most owners rated the quality of life of their cardiac dogs as good to very good, as long as symptoms were medically controlled. Owner information about the course of the disease and medication significantly improved compliance and satisfaction.